Pay in 4 interest-free payments of $5.78 Learn more
Ships within 48 hours · Estimated delivery Oct 10 - Oct 15
Do you feel ready to build a treatment plan
Lilly's 2025 guidance of USD 5861 billion implies continued 32% growth momentum, validated by the SURMOUNT-5 Phase 3b head-to-head trial result: Zepbound demonstrated 47% greater relative weight loss compared to Wegovy the most commercially consequential head-to-head data in the obesity market
The Model S Dual Table is the best seller
A molecular dynamics and circular dichroism study of a novel synthetic antimicrobial peptide
Pain is minimal, and mainly associated with minor discomfort at the injection site with little to no recovery time
US$ 26.84
US$ 28.22
US$ 23.13
US$ 22.58
US$ 25.69
